PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) was the target of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,317 shares, a decline of 23.5% from the February 26th total of 10,866 shares. Currently, 20.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 18,324 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research note on Friday, January 9th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, PicoCELA currently has a consensus rating of “Sell”.

Institutional Trading of PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd acquired a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned about 0.16% of PicoCELA at the end of the most recent reporting period.

PicoCELA Trading Down 4.2%

PCLA opened at $2.06 on Friday. The company has a quick ratio of 1.57, a current ratio of 2.13 and a debt-to-equity ratio of 0.02. PicoCELA has a twelve month low of $1.94 and a twelve month high of $112.20. The company has a 50-day simple moving average of $4.22 and a 200 day simple moving average of $8.38.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.